시장보고서

상품코드

1808837

세계의 EV 기반 액체 생검 시장 : 바이오마커 유형별, 샘플 유형별, 용도별, 최종 사용자별, 국가별, 지역별 산업 분석, 시장 규모, 시장 점유율, 예측(2025-2032년)

EV-Based Liquid Biopsy Market, By Biomarker Type, By Sample Type, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 08월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 365 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

EV 기반 액체 생검 시장의 규모는 2024년 3억 5,523만 달러로 평가되었으며 2025년부터 2032년까지 연평균 복합 성장률(CAGR) 19.5%로 확대될 전망입니다.

EV 기반 액체 생검 시장은 비침습적 진단 도구로서 세포외 소포체(EV)의 사용에 초점을 맞추었습니다. EV는 세포에 의해 혈액, 타액, 소변 등의 체액 중에 자연적으로 방출되는 나노 크기의 입자입니다. 이 소포체는 RNA, DNA, 단백질, 지질과 같은 생물학적 정보를 운반하며, 소포체가 유래하는 세포의 상태를 반영합니다. 이 때문에 질병 중에서도 특히 암의 검출과 모니터링에 유용합니다. 전통적인 생검과는 달리 EV 기반의 액체 생검은 환자의 불편함을 줄이고 질병 진행을 실시간으로 추적할 수 있습니다. 또한 기존의 방법으로는 접근이나 모니터링이 어려운 종양의 검출에도 유리합니다.

정밀의료, 질병의 조기 발견, 저침습 진단에 대한 관심 증가가 이 기술의 채택을 뒷받침하고 있습니다. 게다가 EV는 다른 바이오마커에 비해 순환안정성이 높고 신뢰성을 높이고 있습니다. 현재 진행 중인 연구, 분리기술의 개선, 보다 광범위한 임상 응용으로 시장이 확대되고 있습니다. 표준화와 규제의 명확화 부족 등의 과제에도 불구하고 EV 기반의 액체 생검은 최신의 진단에 있어 유망한 툴로서 대두되고 있습니다.

EV 기반 액체 생검 시장 - 시장 역학

원내 감염 대책 프로토콜의 고조가 주사기 자동 처리 기기 수요를 견인

EV 기반 액체 생검 시장의 주요 틈새 촉진 요인은 세포외 소포체(EV) 바이오마커를 이용한 비침습적 암 모니터링에 대한 수요 증가입니다. 종래의 암 진단에서는 주로 침습적인 조직 생검에 의지하였으나 통증을 수반해 리스크가 높고, 특히 손이 닿지 않는 장소에 있는 종양에 대해서는 실시가 어려울 수 있습니다. 암세포에서 체액 중에 방출되는 EV는 종양의 상태를 반영하는 유전자와 프로테옴 정보를 가지고 있습니다. 이를 통해 임상의는 혈액과 같은 간단한 체액 샘플로 암 진행, 치료 반응, 재발을 추적할 수 있습니다.

연속 샘플링이 가능하기 때문에 환자에게 침습적인 치료를 반복하지 않고 실시간 모니터링이 가능합니다. 게다가, EV는 무세포 DNA와 같은 다른 바이오마커보다 순환 측면에서 안정적이어서 결과의 신뢰성을 향상시킵니다. 종양학이 개인화 및 정밀 기반 접근법으로 이동함에 따라, EV 기반 생검은 치료를 조정하는 중요한 도구가 되고 있습니다. 그 역할은 환자의 건강 상태와 종양의 위치로 인해 조직 생검이 불가능할 때 특히 중요합니다. 이러한 임상 수요 증가는 EV 기반 진단의 기술 혁신과 투자를 촉진하고 있습니다.

EV 기반 액체 생검 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2025-2032년)에 약 19.5%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예측되고 있습니다.

바이오마커 유형별로는 마이크로 RNA(miRNA)와 메신저 RNA(mRNA)가 2024년 최대 시장 점유율을 보였습니다.

샘플 유형별로는 혈액은 2024년의 주요 샘플 유형으로 나타났습니다.

용도별로는 암 진단이 2024년의 주요 용도로 나타났습니다.

지역별로는 북미가 2024년에 최고 매출을 달성하였습니다.

EV 기반 액체 생검 시장 - 세분화 분석

세계의 EV 기반 액체 생검 시장은 바이오마커 유형, 샘플 유형, 용도, 최종 사용자, 지역에 따라 세분화됩니다.

시장은 바이오마커 유형에 따라 단백질, RNA(miRNA, mRNA 등), DNA, 지질의 네 가지 범주로 나뉩니다. EV 기반 액체 생검 시장에서 바이오마커 유형 중에서 마이크로 RNA(miRNA)와 메신저 RNA(mRNA)를 포함한 RNA가 가장 지배적인 부문으로 부상하고 있습니다. 이 우위성은 RNA가 기원세포 중에서도 특히 암세포의 유전적 활성을 반영하는데 중요한 역할을 하고 있기 때문입니다. EV는 안정된 RNA 분자를 운반하고 유전자 발현 패턴에 대한 귀중한 인사이트를 제공하여 질병의 조기 발견과 모니터링을 가능하게 합니다.

다른 생체분자에 비해 RNA 바이오마커는 정확한 진단과 예후에 필수적인 높은 특이성과 감도를 제공합니다. 게다가 RNA 시퀀싱과 해석 기술의 진보에 의해 EV 관련 RNA를 확실하게 검출 및 정량하는 능력이 향상하고 있습니다. 개인화된 의료에 대한 관심 증가는 RNA 바이오마커의 사용을 더욱 강화하고 있습니다. EV에서 순수한 RNA를 분리하는 어려움에도 불구하고, 현재 진행 중인 조사는 이러한 장애를 극복하고 있으며, RNA의 지위는 이 시장의 주요 견인 역할로 확고합니다.

시장은 애플리케이션을 기반으로 암 진단, 감염, 신경 질환, 심혈관 질환, 기타 유형의 다섯 가지 범주로 나뉩니다. EV 기반 액체 생검 시장에서는 암 진단이 가장 우세한 샘플 유형 부문입니다. 이 우위성은 암을 조기에 정확하고 저침습으로 검출 및 감시하는 방법에 대한 중요한 요구로부터 발생하고 있습니다. 종양 세포에서 방출되는 세포외 소포체는 단백질, RNA, DNA 등의 분자 서명을 가지며, 종양의 존재, 진행, 치료에 대한 반응에 대한 실시간 정보를 제공합니다. 전통적인 조직 생검과는 달리, EV 기반의 액체 생검은 단순한 혈액과 체액 샘플을 통한 지속적인 모니터링을 가능하게 하여 환자의 불편함을 줄이고 조기 개입을 가능하게 합니다.

세계적인 암 이환율의 상승과 맞춤형 의료의 중시 증가가 종양학에서의 EV 기반 진단의 채용을 더욱 뒷받침하고 있습니다. 게다가 이러한 액체 생검은 전통적인 방법으로 접근과 모니터링이 어려운 종양의 검출에 도움이 됩니다. 조사와 임상시험을 통해 암 검출에 있어서의 EV 바이오마커의 유효성을 계속 검증하고 있으며, 이 샘플 유형이 시장의 주요 성장 요인이 되고 있습니다. 감염과 신경 질환과 같은 다른 샘플 유형이 상승하고 있는 반면, 암 진단은 현재 EV 기반의 액체 생검 개발과 상업화에 초점을 맞추었습니다.

EV 기반 액체 생검 시장 - 지리적 인사이트

북미에서는 첨단 건강 관리 인프라와 혁신적인 진단 기술의 조기 도입으로 EV 기반 액체 생검 시장이 강력한 기세를 보이고 있습니다. 이 지역은 암 진단에 중점을 둔 학술 기관, 생명 공학 기업, 정부의 자금 지원 이니셔티브에 의해 지원되는 견고한 연구 생태계의 혜택을 누리고 있습니다. 비침습적 질환 검출 및 모니터링에서 세포외 소포체의 임상적 가치에 대해 의료 전문가들 사이에서 인식이 증가하고 있습니다. EV 기반 검사와 임상의 통합은 확립된 규제 프레임워크와 진행 중인 임상 시험의 존재에 의해 촉진됩니다.

미국은 EV 기반 액체 생검 시장의 최전선에 있으며, 그 원동력은 선진적인 헬스케어 인프라와 암의 조기 발견에 대한 강한 강조입니다. 일류 학술 기관과 최종 사용자 바이오 기업을 포함하는 이 나라의 견고한 연구 생태계는 진단 기술의 끊임없는 혁신을 촉진하고 있습니다. 임상의와 환자 사이에 비침습적 진단법에 대한 선호도가 높아지면서 EV 기반 액체 생검의 채용이 가속화되어 병의 진행과 치료 반응에 대한 실시간 인사이트를 제공합니다. 미국 식품의약국(FDA)은 이러한 신흥 기술을 규제하는 데 매우 중요한 역할을 하고 있으며, 안전성과 유효성의 기준이 충족되고 있음을 보증하고 있습니다. 그러나 EV 분리 및 분석을 위한 표준화된 프로토콜의 필요성과 같은 문제는 여전히 남아 있습니다.

EV 기반 액체 생검 시장 - 경쟁 구도

EV 기반 액체 생검 시장의 경쟁 구도는 기존의 최종 사용자 바이오 기업과 세포외 소포체 기술에 특화된 혁신적인 신흥 기업이 혼재하여 형성되고 있습니다. Exosome Diagnostics, Thermo Fisher Scientific, Qiagen 등의 기업은 강력한 연구 능력과 세계적인 리치를 활용하여 EV 기반 진단을 진행하는 유력한 기업입니다. Bio-Techne Corporation과 NanoView Biosciences도 EV 검출 및 특성화 기술 혁신을 통해 크게 발전하고 있습니다. 한편, 시스템 바이오사이언시스(SBI), 밀테니 바이오텍(Miltenyi Biotec), AMSBIO는 특수한 EV 분리 및 분석 키트를 제공합니다.

Exosomics SpA, Codiak BioSciences, VivaZome Therapeutics와 같은 신흥 기업은 종양학과 맞춤형 의료에 맞는 새로운 EV 기반 플랫폼을 개발함으로써 경쟁을 격화시키고 있습니다. 시장은 매우 역동적이며 전략적 공동 연구, 연구 제휴 및 임상 검증이 경쟁적 위치를 형성하는 데 중요한 역할을 합니다. 규제의 경로가 명확해짐에 따라 이들 기업은 임상 현장에서의 존재감을 높여 나갈 것으로 예측됩니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - EV 기반의 액체 생검 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 프로파일
- Exosome Diagnostics
- Bio-Techne Corporation
- Thermo Fisher Scientific
- NanoView Biosciences
- System Biosciences(SBI)
- Qiagen
- Norgen Biotek Corp.
- BioVision Inc.
- Miltenyi Biotec
- Creative Biolabs
- AMSBIO
- Exosomics SpA
- NX Pharmagen
- VivaZome Therapeutics
- Aethlon Medical
- Evox Therapeutics
- Capricor Therapeutics
- Codiak BioSciences
- Anjarium Biosciences
- HansaBioMed Life Sciences

제13장 애널리스트의 종합적 전망

CSM 25.09.25

EV-Based Liquid Biopsy Market size was valued at US$ 355.23 Million in 2024, expanding at a CAGR of 19.5% from 2025 to 2032.

The EV-based liquid biopsy market focuses on the use of extracellular vehicles (EVs) as a non-invasive diagnostic tool. EVs are nano-sized particles naturally released by cells into bodily fluids such as blood, saliva, and urine. These vesicles carry biological information, like RNA, DNA, proteins, and lipids, that reflects the state of their originating cells. This makes them valuable for detecting and monitoring diseases, especially cancers. Unlike traditional biopsies, EV-based liquid biopsies reduce patient discomfort and enable real-time tracking of disease progression. They are also advantageous for detecting tumors that are difficult to access or monitor using conventional methods.

Growing interest in precision medicine, early disease detection, and less invasive diagnostics is driving the adoption of this technology. Additionally, EVs are more stable in circulation compared to other biomarkers, which enhances their reliability. The market is expanding due to ongoing research, improved isolation techniques, and broader clinical applications. Despite some challenges, including a lack of standardization and regulatory clarity, EV-based liquid biopsy is emerging as a promising tool in modern diagnostics.

EV-Based Liquid Biopsy Market- Market Dynamics

Rising hospital-acquired infection control protocols drive demand for needle destroyers.

A key niche driver for the EV-based liquid biopsy market is the growing demand for non-invasive cancer monitoring using extracellular vesicle (EV) biomarkers. Traditional cancer diagnostics often rely on invasive tissue biopsies, which can be painful, risky, and not always feasible, especially for tumors in inaccessible locations. EVs, released by cancer cells into body fluids, carry genetic and proteomic information that mirrors the tumor's state. This enables clinicians to track cancer progression, therapeutic response, or recurrence with simple fluid samples like blood.

The ability to perform serial sampling offers real-time monitoring without subjecting patients to repeated invasive procedures. Additionally, EVs are more stable in circulation than other biomarkers like cell-free DNA, improving result reliability. As oncology shifts toward personalized and precision-based approaches, EV-based biopsies are becoming a valuable tool for tailoring treatments. Their role is particularly significant in cases where tissue biopsy is not possible due to the patient's health or tumor location. This rising clinical demand continues to propel innovation and investment in EV-based diagnostics.

EV-Based Liquid Biopsy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 19.5% over the forecast period (2025-2032)

Based on Biomarker Type segmentation, microRNA (miRNA) and messenger RNA (mRNA), were predicted to show maximum market share in the year 2024

Based on Sample Type segmentation, Blood was the leading Sample Type in 2024

Based on Application segmentation, Cancer diagnostics was the leading Application in 2024

Based on region, North America was the leading revenue generator in 2024

EV-Based Liquid Biopsy Market- Segmentation Analysis:

The Global EV-Based Liquid Biopsy Market is segmented based on Biomarker Type, Sample Type, Application, End-user, and Region.

The market is divided into four categories based on Biomarker Type. Proteins, RNA (miRNA, mRNA, etc.), DNA, Lipids, Others. Among the biomarker types in the EV-based liquid biopsy market, RNA, including microRNA (miRNA) and messenger RNA (mRNA), emerges as the most dominant segment. This prominence is due to the critical role RNA plays in reflecting the genetic activity of originating cells, especially cancer cells. EVs carry stable RNA molecules that provide valuable insights into gene expression patterns, enabling early disease detection and monitoring.

Compared to other biomolecules, RNA biomarkers offer high specificity and sensitivity, which are essential for accurate diagnosis and prognosis. miRNAs, in particular, regulate various cellular processes and have been linked to tumor progression, making them powerful indicators in liquid biopsies. Additionally, advances in RNA sequencing and analysis technologies have improved the ability to detect and quantify EV-associated RNAs reliably. The growing focus on personalized medicine further supports the use of RNA biomarkers, as they help tailor treatments based on molecular profiles. Despite challenges in isolating pure RNA from EVs, ongoing research is overcoming these obstacles, cementing RNA's position as a key driver in this market.

The market is divided into five categories based on Application: Cancer Diagnostics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, and Others. Cancer diagnostics is the most dominant Sample Type segment in the EV-based liquid biopsy market. This dominance stems from the critical need for early, accurate, and minimally invasive methods to detect and monitor cancer. Extracellular vesicles released by tumor cells carry molecular signatures such as proteins, RNA, and DNA that provide real-time information about tumor presence, progression, and response to treatment. Unlike traditional tissue biopsies, EV-based liquid biopsies allow for continuous monitoring through simple blood or body fluid samples, reducing patient discomfort and enabling earlier intervention.

The rising global cancer burden and increasing emphasis on personalized medicine have further driven the adoption of EV-based diagnostics in oncology. Additionally, these liquid biopsies help detect tumors that are difficult to access or monitor through conventional methods. Research and clinical trials continue to validate the efficacy of EV biomarkers in cancer detection, making this Sample Type the primary growth driver for the market. While other Sample Types like infectious diseases and neurological disorders are emerging, cancer diagnostics currently remain the focal point of EV-based liquid biopsy development and commercialization.

EV-Based Liquid Biopsy Market- Geographical Insights

In North America, the EV-based liquid biopsy market is experiencing strong momentum due to advanced healthcare infrastructure and early adoption of innovative diagnostic technologies. The region benefits from a robust research ecosystem supported by academic institutions, biotech companies, and government funding initiatives focused on cancer diagnostics. There is a growing awareness among healthcare professionals about the clinical value of extracellular vesicles in non-invasive disease detection and monitoring. The integration of EV-based tests into clinical practice is facilitated by the presence of well-established regulatory frameworks and ongoing clinical trials.

The United States is at the forefront of the EV-based liquid biopsy market, driven by its advanced healthcare infrastructure and strong emphasis on early cancer detection. The country's robust research ecosystem, encompassing leading academic institutions and bioEnd-user firms, fosters continuous innovation in diagnostic technologies. A growing preference for non-invasive diagnostic methods among clinicians and patients has accelerated the adoption of EV-based liquid biopsies, which offer real-time insights into disease progression and treatment response. The U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these emerging technologies, ensuring safety and efficacy standards are met. However, challenges persist, including the need for standardized protocols for EV isolation and analysis.

EV-Based Liquid Biopsy Market- Competitive Landscape:

The competitive landscape of the EV-based liquid biopsy market is shaped by a mix of established bioend-user firms and innovative startups focused on extracellular vesicle technologies. Companies such as Exosome Diagnostics, Thermo Fisher Scientific, and Qiagen are prominent players, leveraging their strong research capabilities and global reach to advance EV-based diagnostics. Bio-Techne Corporation and NanoView Biosciences are also making significant strides through technological innovations in EV detection and characterization. Meanwhile, System Biosciences (SBI), Miltenyi Biotec, and AMSBIO are contributing specialized EV isolation and analysis kits.

Emerging companies like Exosomics S.p.A, Codiak BioSciences, and VivaZome Therapeutics are intensifying competition by developing novel EV-based platforms tailored for oncology and personalized medicine. The market is highly dynamic, with strategic collaborations, research partnerships, and clinical validations playing a key role in shaping competitive positioning. As regulatory pathways become clearer, these companies are expected to expand their presence in clinical settings.

Recent Developments:

In October 2024, QIAGEN expanded its automated liquid biopsy portfolio to enhance oncology, prenatal care, and organ transplant applications. The new ccfDNA Kit upgrade with a urine protocol for EZ1 and 2 instruments is designed to improve liquid biopsy workflows for cancer research. The QIAsymphony DSP Circulating DNA and Maxi Kits deliver high-quality cfDNA for downstream applications.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL EV-BASED LIQUID BIOPSY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Exosome Diagnostics
Bio-Techne Corporation
Thermo Fisher Scientific
NanoView Biosciences
System Biosciences (SBI)
Qiagen
Norgen Biotek Corp.
BioVision Inc.
Miltenyi Biotec
Creative Biolabs
AMSBIO
Exosomics S.p.A
NX Pharmagen
VivaZome Therapeutics
Aethlon Medical
Evox Therapeutics
Capricor Therapeutics
Codiak BioSciences
Anjarium Biosciences
HansaBioMed Life Sciences

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2019 - 2032

Proteins
RNA (miRNA, mRNA, etc.)
DNA
Lipids
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

Blood
Urine
Saliva
Cerebrospinal Fluid
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

Cancer Diagnostics
Infectious Diseases
Neurological Disorders
Cardiovascular Diseases
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Research Institutes
Diagnostic Laboratories
Biopharmaceutical Companies
Others

GLOBAL EV-BASED LIQUID BIOPSY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. EV-Based Liquid Biopsy Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. EV-Based Liquid Biopsy Market Snippet by Biomarker Type
- 2.1.2. EV-Based Liquid Biopsy Market Snippet by Sample Type
- 2.1.3. EV-Based Liquid Biopsy Market Snippet by Application
- 2.1.4. EV-Based Liquid Biopsy Market Snippet by End-user
- 2.1.5. EV-Based Liquid Biopsy Market Snippet by Country
- 2.1.6. EV-Based Liquid Biopsy Market Snippet by Region
2.2. Competitive Insights

3. EV-Based Liquid Biopsy Key Market Trends

3.1. EV-Based Liquid Biopsy Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. EV-Based Liquid Biopsy Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. EV-Based Liquid Biopsy Market Opportunities
3.4. EV-Based Liquid Biopsy Market Future Trends

4. EV-Based Liquid Biopsy Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. EV-Based Liquid Biopsy Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. EV-Based Liquid Biopsy Market Landscape

6.1. EV-Based Liquid Biopsy Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. EV-Based Liquid Biopsy Market - By Biomarker Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Biomarker Type, 2024 & 2032 (%)
- 7.1.2. Proteins
- 7.1.3. RNA (miRNA, mRNA, etc.)
- 7.1.4. DNA
- 7.1.5. Lipids
- 7.1.6. Others

8. EV-Based Liquid Biopsy Market - By Sample Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Sample Type, 2024 & 2032 (%)
- 8.1.2. Blood
- 8.1.3. Urine
- 8.1.4. Saliva
- 8.1.5. Cerebrospinal Fluid
- 8.1.6. Others

9. EV-Based Liquid Biopsy Market - By Application

9.1. Overview
- 9.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
- 9.1.2. Cancer Diagnostics
- 9.1.3. Infectious Diseases
- 9.1.4. Neurological Disorders
- 9.1.5. Cardiovascular Diseases
- 9.1.6. Others

10. EV-Based Liquid Biopsy Market - By End-user

10.1. Overview
- 10.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
- 10.1.2. Hospitals & Clinics
- 10.1.3. Research Institutes
- 10.1.4. Diagnostic Laboratories
- 10.1.5. Biopharmaceutical Companies
- 10.1.6. Others

11. EV-Based Liquid Biopsy Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. EV-Based Liquid Biopsy Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. EV-Based Liquid Biopsy Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. EV-Based Liquid Biopsy Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. EV-Based Liquid Biopsy Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. EV-Based Liquid Biopsy Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Biomarker Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- EV-Based Liquid Biopsy Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. Exosome Diagnostics
- 12.2.2. Bio-Techne Corporation
- 12.2.3. Thermo Fisher Scientific
- 12.2.4. NanoView Biosciences
- 12.2.5. System Biosciences (SBI)
- 12.2.6. Qiagen
- 12.2.7. Norgen Biotek Corp.
- 12.2.8. BioVision Inc.
- 12.2.9. Miltenyi Biotec
- 12.2.10. Creative Biolabs
- 12.2.11. AMSBIO
- 12.2.12. Exosomics S.p.A
- 12.2.13. NX Pharmagen
- 12.2.14. VivaZome Therapeutics
- 12.2.15. Aethlon Medical
- 12.2.16. Evox Therapeutics
- 12.2.17. Capricor Therapeutics
- 12.2.18. Codiak BioSciences
- 12.2.19. Anjarium Biosciences
- 12.2.20. HansaBioMed Life Sciences

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us